Knight Therapeutics (KHTRF) announced that Health Canada has approved WYNZORA, a white uniform cream containing 0.05 mg/g of calcipotriol and 0.5 mg/g of betamethasone dipropionate, indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.1 Knight obtained the Canadian rights to WYNZORA through its June 2025 acquisition of the assets of Paladin Pharma. In November 2024, Paladin had entered into a license agreement with MC2 Therapeutics to commercialize WYNZORA in Canada. MC2 is a private pharmaceutical company based in Horsholm, Denmark and in Guildford, United Kingdom.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Reports Record Revenues Amid Challenges
- Knight Therapeutics Reports Record Q3 Revenues and Raises Guidance
- Knight Therapeutics Achieves Record-High Revenues in Q3 2025
- Knight Therapeutics reports Q3 EPS (C$0.04) vs. (C$0.00) last year
- Knight Therapeutics sees FY25 revenue C$430M-C$440M